?Exemestane | CAS 107868-30-4?
?? ?Product Overview?
Exemestane, a steroidal aromatase inhibitor with molecular formula ?C??H??O?? and molecular weight ?296.4 g/mol?, is primarily used in the treatment of ?hormone receptor-positive breast cancer? in postmenopausal women?14. It works by irreversibly inhibiting the aromatase enzyme, thereby reducing estrogen synthesis and slowing tumor growth?45. Widely applied in pharmaceuticals and research, it is essential for oncology and endocrine disorder studies?12.

?? ?Key Advantages?
? ?High Purity & Stability?
≥98% purity (USP standards) with ?24-month stability? under ?room temperature, dry, and light-protected storage??12.

?? ?Targeted Efficacy?
Demonstrates potent aromatase inhibition (IC?? = ?27 nM?), validated in preclinical and clinical studies for breast cancer therapy?45.

??? ?Regulatory Compliance?
Manufactured under ?GMP? guidelines and compliant with ?USP? analytical standards, ensuring pharmaceutical-grade quality?24.

?? ?Applications?

• ?Pharmaceuticals?: Core component in ?aromatase inhibitor therapies? for advanced or metastatic breast cancer?

• ?Research?: Used in steroid metabolism studies, anti-aging research, and molecular biology experiments?

• ?Biochemical Synthesis?: Intermediate in steroid hormone production and enzyme inhibition assays?

?? ?Quality Certifications?

• Complies with ?USP? and ?EP? pharmacopeia standards?.

• Batch-specific ?COA (Certificate of Analysis)? and stability reports provided?.

?? ?Market Trends?
The global breast cancer therapeutics market is projected to grow at a ?CAGR of 7.3% (2025-2030)?, driven by rising oncology R&D and demand for targeted hormone therapies?5. Exemestane remains a critical agent in personalized cancer treatment regimens.